Belgium· BE-AMP-SAM178586-00

Crixivan 200 mg

A indinavir product containing indinavir sulfate, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 4 of our 19 countries.

ATC J05AE02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedCrixivan 200 mgATCJ05AE02REGISTER NO.BE-AMP-SAM178586-00PACKS LISTED1CHECKEDSeptember 26, 2026

Where it is registered

Indinavir is registered in 4 of 19 countries.

Countries holding a registration under ATC J05AE02 (indinavir), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 3 of them publish a price we can compare per daily dose

Indinavir · ATC J05AE02

4 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Indinavir Sulfate
Manufacturer
Merck Sharp & Dohme
Country
Belgium (BE)
ATC code
J05AE02
ATC class
Indinavir
Defined daily dose
2.4 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    1294495

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

353 interactions on record for indinavir.

Graded by severity as the source publishes them — 124 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Indinavir · interactions on record

353 records

  • 124 severe
  • 171 moderate
  • 20 minor
  • 18 info

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • LoperamideA07DA03severe
  • BudesonideA07EA06severe

20 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Indinavir in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All indinavir products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4dcd622c-e4f1-4e65-b6e7-58a11c55c25f
GET /v1/drugs/4dcd622c-e4f1-4e65-b6e7-58a11c55c25f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Crixivan 200 mg",
  "name_fr": "Crixivan 200 mg",
  "name_nl": "Crixivan 200 mg",
  "amp_code": "SAM178586-00",
  "strengths": [
    "200.0000",
    "200.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Indinavir Sulfate",
    "Indinavir"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Indinavir",
  "authorisation_numbers": [
    "EU/1/96/024/003",
    "EU/1/96/024/001",
    "EU/1/96/024/002"
  ]
}

See everything about indinavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.